A Phase II, Single-Arm Study of Ribociclib (LEE011), Everolimus, and Letrozole, in Patients With Advanced or Recurrent Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary) ; Ribociclib (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Aug 2017 Planned End Date changed from 1 Sep 2022 to 1 Aug 2022.
- 21 Aug 2017 Planned primary completion date changed from 1 Sep 2022 to 1 Aug 2022.
- 21 Aug 2017 Status changed from not yet recruiting to recruiting.